论文部分内容阅读
目的分析新型抗结核药物左氧氟沙星联合其他抗结核药物治疗重度肺结核患者的治疗效果和安全性。方法对100例重症肺结核患者采用1∶1随机、平行对照的方法,分为左氧氟沙星治疗组(治疗组)和常规治疗组(对照组),完成6个月疗程后,随访2年,进行统计分析。结果治疗组和对照组的痰菌阴转情况、药物不良反应情况差异无统计学意义;胸部X线显示病灶吸收率治疗组和对照组的差异有统计学意义,治疗2月末为72%和46%,(χ2=9.24,P<0.01);治疗6月末为78%和52%,(χ2=7.428,P<0.01)。结论初治涂阳的重症肺结核患者可考虑联用左氧氟沙星抗结核治疗,提高治疗效果。
Objective To analyze the therapeutic effect and safety of new anti-tuberculosis drug levofloxacin in combination with other anti-tuberculosis drugs in patients with severe pulmonary tuberculosis. Methods 100 cases of severe pulmonary tuberculosis patients were divided into two groups: levofloxacin group (treatment group) and conventional treatment group (control group) by 1: 1 randomized and parallel control. After 6 months of treatment, the patients were followed up for 2 years and statistically analyzed . Results There was no significant difference in sputum negative conversion and adverse drug reactions between the treatment group and the control group. The chest X-ray showed that the absorption rate of the lesions was significantly different between the treatment group and the control group, with 72% and 46 %, (χ2 = 9.24, P <0.01). The treatment end was 78% and 52% at the end of June (χ2 = 7.428, P <0.01). Conclusion The newly diagnosed smear-positive patients with severe pulmonary tuberculosis may consider levofloxacin combined with anti-TB therapy to improve the therapeutic effect.